PIN Pharma, a pre-clinical immunotherapy company focused on modulating the immune system in oncology, today announced the Company will be presenting PIN-2: A Novel Immunopriming Peptide with Immunomodulatory Activity Linking the Innate and Adaptive Immune Systems at Poster Session B on Monday, September 26, 2016 from 5:30 pm – 8:00 pm.
About PIN Pharma, Inc.
PIN Pharma is a pre-clinical stage venture backed immunotherapy company focused on the development of PINS (precision immune stimulants). The lead compound PIN-2 is a first-in-class, novel, next-generation engineered peptide that empowers the immune system in vivo. The Company’s technology primes the innate immune system to modulate adaptive immunity thereby generating and expanding antigen-specific cytotoxic T-cells in vivo. The company is advancing PIN-2 to the clinic early first quarter 2017.
For more information about PIN Pharma and PIN-2, contact Mark Smith, CBO (firstname.lastname@example.org) or Colin Bier, CEO (email@example.com) at PIN Pharma, Inc., 3960 Broadway, Suite 620, New York, NY, or call 212-543-2583.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160919005128/en/Business Wire
Last updated on: 19/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.